Achieving Improved Survival Outcomes in Advanced Breast Cancer
Author:
- 25 July 2019
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 381 (4) , 371-372
Abstract
Breast cancer is the most common cancer diagnosis in young women.1 In the United States, the incidence of breast cancer among women under the age of 50 is increasing by 0.2% per year, and the incidence of distant disease at the time of diagnosis among patients with hormone-receptor–positive breast cancer increased by about 2% per year between 1976 and 2009.2 A young age at diagnosis has been associated with worse outcomes and less sensitivity to endocrine therapy. Small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have changed the standard of care for patients with advanced hormone-receptor–positive breast cancer. The . . .Keywords
This publication has 9 references indexed in Scilit:
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerNew England Journal of Medicine, 2019
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2019
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancernpj Breast Cancer, 2019
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upBreast Cancer Research and Treatment, 2019
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNew England Journal of Medicine, 2018
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialThe Lancet Oncology, 2018
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnnals of Oncology, 2018
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009JAMA, 2013